In the current study, we have performed an extensive preclinical drug screening and subsequent mechanistical investigation based on classical chemotherapies and innovative targeted agents, using two different adrenocortical cancer cell lines: the classical NCI- H295R cell line and the more recently developed and highly drug-resistant MUC-1 cell line [11,18,19,20,21,22,23]. The gene discussed is MUC1; the disease is adrenal cortex carcinoma.